Abstract
Rituximab is a monoclonal antibody intended for the treat- ment of various autoimmune conditions as well as B-cell lymphoid malignancies. It is targeted to the CD20 antigen, which induces apoptosis in mature B cells, making it a useful therapeutic agent against B-cell lymphoid malignancies when used in conjunction with cytotoxic che- motherapy regimens such as cyclophosphamide, hydroxydaunorubicin (doxorubicin), Oncovin (vincristine; Hospira Inc, Lake Forest Ill), and prednisone/prednisolone. It is a very successful treatment of B-cell ma- lignancies but causes profound immunosuppression and elevates the risk of opportunistic infections such as enterovirus meningitis. We report a case of aseptic meningitis in a patient with non-Hodgkin lymphoma after treatment with rituximab in combination with cytotoxic chemotherapy and successful treatment with intravenous immunoglobulin therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
